Comparative Effectiveness of Adjuvant Chemotherapy in Early-Stage Breast Cancer: A Network Meta-analysis



      There are several regimens recommended by the National Comprehensive Cancer Network (NCCN) for HER2-negative operable breast cancer. To our knowledge, no trials have yet been performed comparing these regimens head to head. We performed a network meta-analysis comparing the efficacy of NCCN-recommended chemotherapy regimens.


      We searched Medline, Embase, Web of Science, the Cochrane Central Register of Controlled Trials, and World Health Organization (WHO) International Clinical Trials Registry Platform from inception to February 2020. We included randomized clinical trials comparing adjuvant regimens in predominantly node-positive operable breast cancer patients. We compared (1) DDACT, (2) TCx4 cycles, (3) TAC, and (4) ACWKT. Common comparators were (5) AC, (6) ACT, and (7) ACD. Preferred Reporting Items for Systematic Reviews and Meta-analysis (PRISMA) guidelines were followed. The Cochrane risk of bias tool assessed quality of the studies. Odds ratios (ORs) were calculated as measures of treatment effects with AC as reference. We used Bayesian hierarchical random-effects models with noninformative priors for mixed multiple treatment comparisons. Effectiveness was estimated by disease-free and overall survival using ORs. Sensitivity analyses were performed. Safety outcomes included febrile neutropenia.


      We identified 7 randomized controlled trials with 16,332 patients. TC (odds ratio [95% confidence interval], 0.71 [0.36-1.40]), TAC (0.77 [0.37-1.57]), ACWKT (0.68 [0.34-1.38]), and DDACT (0.72 [0.35-1.42]) were similar for overall survival. TC (0.64 [0.36-1.14]), TAC (0.67 [0.39-1.15]), ACWKT (0.63 [0.37-1.07]), and DDACT (0.59 [0.35-1.01]) had similar disease-free survival benefit. With regard to toxicity, TAC (2.67 [0.30-21.04]) had the highest odds of febrile neutropenia.


      The current generation of regimens are similar in efficacy. Given the lower toxicity of TCx4 comparatively, it is an acceptable alternative for lower-risk early-stage HER2-negative breast cancers.


      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'


      Subscribe to Clinical Breast Cancer
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect


      1. Surveillance, Epidemiology, and End Results (SEER). Program research. Data cancer stat facts: female breast cancer. National Cancer Institute; 2019. Accessed: 16 June, 2019.

        • Bonadonna G.
        • Brusamolino E.
        • Valagussa P.
        • et al.
        Combination chemotherapy as an adjuvant treatment in operable breast cancer.
        N Engl J Med. 1976; 294: 405-410
        • Fisher B.
        • Brown A.M.
        • Dimitrov N.V.
        • et al.
        Two months of doxorubicin–cyclophosphamide with and without interval reinduction therapy compared with 6 months of cyclophosphamide, methotrexate, and fluorouracil in positive-node breast cancer patients with tamoxifen-nonresponsive tumors: results from the National Surgical Adjuvant Breast and Bowel Project B-15.
        J Clin Oncol. 1990; 8: 1483-1496
        • National Comprehensive Cancer Network
        NCCN clinical practice guidelines in oncology: breast cancer, version 2.2020.
        (Available at:)
        • Riva S.
        • Pravettoni G.
        Value-based model: a new perspective in medical decision-making.
        Front Public Health. 2016; 4: 118
        • Citron M.L.
        • Berry D.A.
        • Cirrincione C.
        • et al.
        Randomized trial of dose-dense versus conventionally scheduled and sequential versus concurrent combination chemotherapy as postoperative adjuvant treatment of node-positive primary breast cancer: first report of Intergroup Trial C9741/Cancer and Leukemia Group B Trial 9741.
        J Clin Oncol. 2003; 21: 1431-1439
        • Sparano J.A.
        • Zhao F.
        • Martino S.
        • et al.
        Long-term follow-up of the E1199 phase III trial evaluating the role of taxane and schedule in operable breast cancer.
        J Clin Oncol. 2015; 33: 2353-2360
        • Mackey J.R.
        • Pienkowski T.
        • Crown J.
        • et al.
        Long-term outcomes after adjuvant treatment of sequential versus combination docetaxel with doxorubicin and cyclophosphamide in node-positive breast cancer: BCIRG-005 randomized trial.
        Ann Oncol. 2016; 27: 1041-1047
        • Jones S.E.
        • Savin M.A.
        • Holmes F.A.
        • et al.
        Phase III trial comparing doxorubicin plus cyclophosphamide with docetaxel plus cyclophosphamide as adjuvant therapy for operable breast cancer.
        J Clin Oncol. 2006; 24: 5381-5387
        • Fujii T.
        • Le Du F.
        • Xiao L.
        • et al.
        Effectiveness of an adjuvant chemotherapy regimen for early-stage breast cancer: a systematic review and network meta-analysis.
        JAMA Oncol. 2015; 1: 1311-1318
        • Blum J.L.
        • Flynn P.J.
        • Yothers G.
        • et al.
        Anthracyclines in early breast cancer: the ABC Trials-USOR 06-090, NSABP B-46-I/USOR 07132, and NSABP B-49 (NRG Oncology).
        J Clin Oncol. 2017; 35: 2647-2655
        • Harbeck N.
        • Gluz O.
        • Clemens M.R.
        • et al.
        Prospective WSG phase III PlanB trial: final analysis of adjuvant 4xEC→4x doc vs 6x docetaxel/cyclophosphamide in patients with high clinical risk and intermediate-to-high genomic risk HER2-negative, early breast cancer.
        J Clin Oncol. 2017; : 504
        • Li T.
        • Puhan M.A.
        • Vedula S.S.
        • Singh S.
        • Dickersin K.
        • Ad Hoc Network Meta-analysis Methods Meeting Working Group
        Network meta-analysis-highly attractive but more methodological research is needed.
        BMC Med. 2011; 9: 79
        • Loke Y.K.
        • Price D.
        • Herxheimer A.
        • Cochrane Adverse Effects Methods Group
        Systematic reviews of adverse effects: framework for a structured approach.
        BMC Med Res Methodol. 2007; 7: 32
        • Higgins J.P.
        • Altman D.G.
        • Gotzsche P.C.
        • et al.
        The Cochrane Collaboration’s tool for assessing risk of bias in randomised trials.
        BMJ. 2011; 343: d5928
        • Lu G.
        • Ades A.E.
        Combination of direct and indirect evidence in mixed treatment comparisons.
        Stat Med. 2004; 23: 3105-3124
        • Dias S.
        • Sutton A.J.
        • Ades A.E.
        • Welton N.J.
        Evidence synthesis for decision making 2: a generalized linear modeling framework for pairwise and network meta-analysis of randomized controlled trials.
        Med Decis Making. 2013; 33: 607-617
        • Dias S.
        • Welton N.J.
        • Caldwell D.M.
        • Ades A.E.
        Checking consistency in mixed treatment comparison meta-analysis.
        Stat Med. 2010; 29: 932-944
        • Mamounas E.P.
        • Bryant J.
        • Lembersky B.
        • et al.
        Paclitaxel after doxorubicin plus cyclophosphamide as adjuvant chemotherapy for node-positive breast cancer: results from NSABP B-28.
        J Clin Oncol. 2005; 23: 3686-3696
        • Eiermann W.
        • Pienkowski T.
        • Crown J.
        • et al.
        Phase III study of doxorubicin/cyclophosphamide with concomitant versus sequential docetaxel as adjuvant treatment in patients with human epidermal growth factor receptor 2–normal, node-positive breast cancer: BCIRG-005 trial.
        J Clin Oncol. 2011; 29: 3877-3884
        • Swain S.M.
        • Tang G.
        • Geyer Jr., C.E.
        • et al.
        Definitive results of a phase III adjuvant trial comparing three chemotherapy regimens in women with operable, node-positive breast cancer: the NSABP B-38 trial.
        J Clin Oncol. 2013; 31: 3197-3204
        • Watanabe T.
        • Kuranami M.
        • Inoue K.
        • et al.
        Comparison of an AC-taxane versus AC-free regimen and paclitaxel versus docetaxel in patients with lymph node-positive breast cancer: final results of the National Surgical Adjuvant Study of Breast Cancer 02 trial, a randomized comparative phase 3 study.
        Cancer. 2017; 123: 759-768
        • Shulman L.N.
        • Cirrincione C.T.
        • Berry D.A.
        • et al.
        Six cycles of doxorubicin and cyclophosphamide or Paclitaxel are not superior to four cycles as adjuvant chemotherapy for breast cancer in women with zero to three positive axillary nodes: Cancer and Leukemia Group B 40101.
        J Clin Oncol. 2012; 30: 4071-4076
        • Henderson I.C.
        • Berry D.A.
        • Demetri G.D.
        • et al.
        Improved outcomes from adding sequential paclitaxel but not from escalating doxorubicin dose in an adjuvant chemotherapy regimen for patients with node-positive primary breast cancer.
        J Clin Oncol. 2003; 21: 976-983